BioCentury
ARTICLE | Clinical News

ONO-4641: Phase II data

April 23, 2012 7:00 AM UTC

The double-blind, international Phase II DreaMS trial in 407 patients aged 18-55 with RRMS showed that once-daily 0.05, 0.1 and 0.15 mg oral ONO-4641 all met the primary endpoint of reducing the numbe...